OTCM
VCNX
Market cap1mUSD
Jun 16, Last price
0.71USD
1D
-13.41%
1Q
10.94%
IPO
-99.59%
Name
Vaccinex Inc
Chart & Performance
P/E
—
P/S
3.33
EPS
—
Div Yield, %
—
Shrs. gr., 5y
79.51%
Rev. gr., 5y
-4.67%
Revenues
570k
+470.00%
Net income
-20m
L+2.68%
CFO
-17m
L-9.65%
Earnings
Aug 12, 2025
Profile
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 570 470.00% | 100 -88.89% | ||||||
Cost of revenue | 23,455 | 20,388 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (22,885) | (20,288) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | (93) | |||||||
Tax Rate | ||||||||
NOPAT | (22,885) | (20,195) | ||||||
Net income | (20,251) 2.68% | (19,722) -15.11% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 12,519 | 17,050 | ||||||
BB yield | -4,061.52% | -872.74% | ||||||
| Debt | ||||||||
Debt current | 367 | 238 | ||||||
Long-term debt | 172 | 557 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | (996) | (5,596) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (17,234) | (19,074) | ||||||
CAPEX | (67) | (99) | ||||||
Cash from investing activities | (67) | (99) | ||||||
Cash from financing activities | 12,445 | 16,975 | ||||||
FCF | (20,468) | (20,256) | ||||||
| Balance | ||||||||
Cash | 1,535 | 6,391 | ||||||
Long term investments | ||||||||
Excess cash | 1,506 | 6,386 | ||||||
Stockholders' equity | (339,927) | (319,671) | ||||||
Invested Capital | 338,009 | 325,349 | ||||||
ROIC | ||||||||
ROCE | 1,193.17% | |||||||
| EV | ||||||||
Common stock shares outstanding | 464 | 202 | ||||||
Price | 0.66 -93.12% | 9.67 -38.03% | ||||||
Market cap | 308 -84.22% | 1,954 -8.84% | ||||||
EV | (688) | (3,642) | ||||||
EBITDA | (22,766) | (20,081) | ||||||
EV/EBITDA | 0.03 | 0.18 | ||||||
Interest | 1,000 | 2 | ||||||
Interest/NOPBT | ||||||||